|1.||Obstructive Sleep Apnea
|5.||Sleep Apnea Syndromes (Sleep Apnea)
|1.||Redline, Susan: 29 articles (11/2015 - 05/2002)|
|2.||Gozal, David: 19 articles (05/2014 - 02/2002)|
|3.||Henderson-Smart, D J: 19 articles (01/2003 - 01/2000)|
|4.||Tufik, Sergio: 16 articles (08/2015 - 03/2008)|
|5.||Ancoli-Israel, Sonia: 15 articles (03/2015 - 03/2006)|
|6.||Guilleminault, Christian: 15 articles (03/2014 - 02/2004)|
|7.||Bairam, Aida: 13 articles (11/2015 - 04/2006)|
|8.||Dujic, Zeljko: 13 articles (11/2015 - 08/2007)|
|9.||Lorenzi-Filho, Geraldo: 13 articles (08/2015 - 09/2005)|
|10.||Schmidt, Barbara: 12 articles (11/2015 - 01/2005)|
03/01/2006 - "PAP was highly effective, with a reduction in the apnea hypopnea index from 27 +/- 32 to 3 +/- 5/hour, and an improvement in arterial oxygen saturation nadir from 77 +/- 17% to 89 +/- 6%. "
06/01/2012 - "DS markedly improved breathing in the first group (baseline vs DS): apnea hypopnea index (AHI) 70.3 ± 25.8 vs 29.4 ± 6.9 (p=0.013), oxygen desaturation index (ODI): 72.9 ± 24.1/h vs 42.5 ± 14.4 (p=0.031), whereas it had no significant effect in the second group or in the total population. "
08/01/1990 - "A 30- or 60-s delay in oxygen administration after onset of hypoxic apnea caused a marked decrease in the adults' ability to autoresuscitate, without affecting that of the pups. "
12/01/2015 - "The high-adherence group showed significant improvement in daytime sleepiness, apnea-hypopnea index (AHI), oxygen desaturation index, and blood pressure. "
11/01/2015 - "PFO closure significantly improved the apnea-hypopnea index (ΔAHI -7.9±10.4 versus +4.7±13.1 events/h, P=0.0009, PFO closure versus control), the oxygen desaturation index (ΔODI -7.6±16.6 versus +7.6±17.0 events/h, P=0.01), and the number of patients with severe OSA decreased significantly after PFO closure (79% versus 21%, P=0.007). "
|2.||Caffeine (No Doz)FDA LinkGeneric
03/01/2009 - "The rate of overall intellectual impairment has not improved, although impairment was reduced in a recent trial of caffeine therapy for apnea of prematurity, and this remains an important area for study. "
01/01/1989 - "There was a marked decrease in apnea frequency, less variability in breathing patterns, and a shift to the left of the CO2 response curve with caffeine. "
07/01/2015 - "High-dose caffeine was associated with a significant reduction in extubation failure in mechanically ventilated preterm infants (p<0.05), the frequency of apnea (p<0.001), and days of documented apnea (p<0.001). "
09/01/1989 - "This study shows that iv caffeine 10 mg/kg is effective in the control of apnea in otherwise healthy expremature infants between 37 and 44 weeks of postconceptual age. "
06/01/2004 - "Caffeine is widely used for the treatment of apnea in premature neonates. "
|3.||Theophylline (Theon)FDA LinkGeneric
01/01/2001 - "Theophylline is more effective than mask CPAP for preterm infants with apnea. "
01/01/2000 - "Theophylline is more effective than mask CPAP for preterm infants with apnea. "
10/01/1980 - "This dose of theophylline is effective in idiopathic apnea of prematurity and acts as a metabolic stimulant. "
01/01/1980 - "Theophylline at this dose appears to be a safe and effective treatment for idiopathic apnea in premature infants. "
01/01/1999 - "Under CPAP therapy all respiratory variables improved and normalized, while under theophylline only the apnea-hypopnea index and the desaturation index improved but still did not return to normal values. "
04/01/1987 - "The comparison of a nocturnal polygraphic study performed during spontaneous breathing with a study during CPAP administration performed the following night showed a significant reduction in stage 1 and increase in REM, the abolition of obstructive apneas and a significant increase in mean oxyhemoglobin saturation. "
10/01/2001 - "Specifically, stimulation significantly reduced the mean apnea-hypopnea indices in non-rapid eye movement (mean +/- SD episodes per hour, 52.0 +/- 20.4 for baseline nights and 22.6 +/- 12.1 for stimulation nights; P<.001) and rapid eye movement (48.2 +/- 30.5 and 16.6 +/- 17.1, respectively; P<.001) sleep and reduced the severity of oxyhemoglobin desaturations. "
04/01/2006 - "CPAP improved, to within normal limits, the apnea-hypopnea index, total arousal index, and mean oxyhemoglobin saturation (p < or = .001). "
06/01/2005 - "An improvement in both apnea-hypopnea index and minimum arterial oxyhemoglobin saturation occurred consistently in all subjects postnatally. "
12/01/1999 - "Mean values improved from preoperative to postoperative vs nCPAP for apnea index (34.5 to 1.0 vs 2.0, respectively), apnea-hypopnea index (59.2 to 4.7 vs 5.4, respectively), lowest arterial oxyhemoglobin desaturations (72.7% to 88.6% vs 88.6%, respectively), and number of desaturations < 90% (118.8 to 6.6 vs 2.4, respectively). "
|5.||Aminophylline (Carine)FDA LinkGeneric
06/01/2003 - "Aminophylline produced significant improvement in periodic breathing but exerted no significant effect on the other types of apnea. "
11/01/1978 - "The effectiveness of aminophylline in treating apnea in premature infants must be related to its central stimulating effect and not to an improvement in lung function and oxygenation."
08/01/2014 - "This study supports the preventative effects of aminophylline on apnea in extreme premature infants. "
08/01/2014 - "This study aimed to assess the safety and prophylactic effects of aminophylline on the incidence of apnea in premature neonates. "
03/01/2013 - "This study investigated 104 very low birth weight infants using aminophylline 5 mg/kg treating apnea who were hospitalized in our department during 2011-2012. "
|6.||Doxapram (Doxapram Hydrochloride)FDA LinkGeneric
01/01/1992 - "Data suggested that doxapram alone at a dose of 1 mg/kg/h is effective for the treatment of neonatal apnea."
08/01/1991 - "The efficacy of low-dose doxapram therapy (0.2 mg/kg/h) in combination with methylxanthines was evaluated in 20 premature infants with idiopathic apnea unresponsive to methylxanthines alone, and in 13 premature infants with secondary apnea. "
01/01/2007 - "Recent studies, however, have demonstrated the efficacy and safety of doxapram therapy for apnea of prematurity (AOP) using lower doses than those previously tested. "
01/01/2004 - "All trials utilising random or quasi-random patient allocation, in which doxapram was used for the treatment of apnea in preterm infants were included. "
04/01/2001 - "However, because of encouraging results of recent studies regarding the efficacy and safety of therapy for apnea of prematurity (AOP) with lower doses of doxapram than those previously proposed, approximately 60% of Japanese neonatologists continue to use doxapram at small doses. "
|7.||Propofol (Diprivan)FDA LinkGeneric
05/01/1991 - "Apnea was significantly greater in the propofol group, in term of incidence (50% vs 15%; p = 0.025), and duration (92 seg vs 17 seg; p = 0.20). "
05/01/1991 - "Patients in groups 3 and 4 had significantly greater decreases in pulse rate and a greater incidence of apnea than did patients in group 1. There was no correlation between the size of the induction dose and subsequent maintenance requirements of propofol. "
05/01/2013 - "It provided better LMA insertion conditions, improved hemodynamic stability with less prolonged apnea when compared with propofol."
08/01/2012 - "In both study arms, detection of apnea or altered respiration induced withholding propofol administration, stimulation of the patient, chin lift maneuver, or further measures. "
03/01/2009 - "We designed a dose-response study to evaluate the intubating conditions, and the incidence and duration of apnea after i.v. propofol in children. "
08/01/2001 - "Four subjects underwent apnea trials in which AVCO2R provided total carbon dioxide removal during apneic oxygenation, resulting in steady-state PaCO2 values from 57 to 85 mmHg. "
11/01/1987 - "Multiple regression analysis performed in the hypercapnic group to study the determinants of the severity of elevation of arterial carbon dioxide tension (PaCO2) revealed significant contribution from the PaO2, the apnea-plus-hypopnea index (AHI), and the percent predicted forced vital capacity (r2 = 0.56; p less than 0.0001), whereas in the normocapnic patients, PaCO2 related to PaO2 only. "
09/01/2015 - "Mean apnea-hypopnea index, respiratory rate, and the maximum transcutaneous carbon dioxide tension were reduced. "
01/01/2015 - "End-Tidal Carbon Dioxide Measurement during Pediatric Polysomnography: Signal Quality, Association with Apnea Severity, and Prediction of Neurobehavioral Outcomes."
06/01/2013 - "Forced expiratory volume in 1 second in percent-predicted was inversely related to apnea-hypopnea index and increase from baseline end-tidal carbon dioxide (P=.023, rs=-0.58), (P<.001, rs=-0.82). "
|9.||Acetazolamide (Diamox)FDA LinkGeneric
11/01/1984 - "This case is also the first to document with polygraphic sleep recordings the suggested efficacy of acetazolamide (26) in abolishing the apneas of Cheyne-Stokes breathing during sleep. "
01/01/2015 - "Hypoxic chemosensitivity directly correlated with the number of apneas/hypopneas at altitude in the placebo group but not in the acetazolamide group. "
08/01/2014 - "Acetazolamide increased CTO and Spo2 at 2,590 m by mean values of 2% (95% CI, 0%-4%) and 2% (95% CI, 1%-3%), respectively, and reduced the apnea/hypopnea index by 23.4/h (95% CI, 14.0-32.8/h) (P < .05, all changes). "
02/01/2013 - "As acetazolamide can reduce apnea severity in some patients, we examined the effect of acetazolamide on the ventilatory response to spontaneous arousals in CPAP-treated OSA patients. "
12/01/2005 - "Acetazolamide (250 mg) increased nocturnal arterial O(2) saturation by 5% (p < 0.01) and decreased mean nocturnal heart rate by 11% (p < 0.05) and the number of apnea-hypopnea episodes during sleep by 74% (p < 0.05). "
|10.||caffeine citrateFDA LinkGeneric
06/01/2000 - "Caffeine citrate was significantly more effective than placebo in reducing apnea episodes by at least 50% in 6 days (p<0.05), and approached statistical significance (p<0.10) in 3 days. "
02/01/2008 - "Caffeine citrate has been shown to be effective in treating apnea of prematurity. "
03/01/1977 - "The efficacy of caffeine citrate in the management of apnea in the newborn infant was evaluated. "
06/01/2000 - "Caffeine citrate for the treatment of apnea of prematurity: a double-blind, placebo-controlled study."
12/01/2015 - "The use of caffeine citrate for treatment of apnea in very low birth weight infants showed short-term and long-term benefits. "
|1.||Continuous Positive Airway Pressure
09/01/1995 - "Successful treatment of apnea by nasal continuous positive airway pressure dramatically reduced the movements during sleep (from 88.2 to 1.9 per hour). "
01/01/1983 - "Application of nasal continuous positive airway pressure through a modified nasal nitrous mask using a ball-valve resistor resulted in reduction of occlusive apnea to 1.17 episodes per hour of sleep and marked improvement in the quality of sleep."
10/01/2013 - "Continuous positive airway pressure is effective in the reduction of the occurrence of apneas. "
09/01/2013 - "Continuous positive airway pressure (CPAP) is effective in reducing the occurrence of apneas. "
02/01/2008 - "With the vagal nerve stimulator back on, continuous positive airway pressure treatment was effective in normalizing the apnea-hypopnea index. "
10/01/2013 - "This study looked at methods to improve safety margin of apnea during induction of anesthesia in these high-risk patients. "
01/01/1961 - "[The significance of anesthesia and apnea in bronchological studies]."
10/01/2015 - "The most commonly observed complications were desaturation, inadequate anesthesia, and apnea. "
07/01/2015 - "A secondary aim is to compare rates of apnea after anesthesia. "
07/01/2015 - "Additional covariates abstracted included basic demographic data, preoperative body mass index, preoperative apnea-hypopnea index, preoperative Charlson comorbidity index, preoperative American Society of Anesthesiologists score, type of intravenous fluid administered, surgical complexity score, duration of anesthesia, duration of surgery, and the use of planned intensive care unit admission. "
09/01/2015 - "MAD therapy reduced the apnea-hypopnea index (AHI) from 15.8 ± 17.4 events/hour before treatment to 6.2 ± 9.8 events/hour after treatment (P < .001). "
10/01/2014 - "Mean apnea-hypopnea index (AHI) and ESS scores decreased from 17.7 ± 14.6 to 7.5 ± 10.9 and from 8.7 ± 4.9 to 6.5 ± 4.4, respectively, after treatment (P < .001). "
09/01/2012 - "Apnea-hypopnea index (AHI) was determined using polysomnography before (AHI 40.6 ± 18.3 per hour) and after treatment. "
12/01/2011 - "One week after treatment, outcomes related to apnea and hyponasal speech were better in group B than group A. "
05/01/2011 - "After treatment, the apnea hypopnoea index (AHI) decreased and the clinical symptoms had resolved by the end of the treatment period. "
07/01/1995 - "Tracheostomy was avoided in 25 of 28 patients (89 percent), with a marked decrease in apnea (median 90 percent) and hypopnea (median 87 percent) episodes. "
11/01/2015 - "Demographics, medical comorbidities, improvement in apnea/hypopnea index, need for tracheostomy, repeated distraction, and complications were evaluated. "
03/01/2014 - "Recorded variables included associated medical comorbidities, improvement in apnea/hypopnea index, need for tracheostomy, repeat distraction, and complications. "
08/01/2001 - "All patients had retrognathia of greater than 8 mm and obstructive airway symptoms while awake that had resulted in tracheostomy (3), repeated apnea monitor triggering (5), or abnormal sleep study (2). "
10/01/2015 - "Our results indicate that certain polysomnographic parameters such as Apnea Hypopnea Index and maximal end-tidal CO2 are valuable in predicting successful tracheostomy decannulation."
|5.||Intermittent Positive-Pressure Ventilation
02/01/1994 - "We conclude that: (1) TRIO does not increase convective gas transfer from the acini compared to apnea; and (2) transfer of gas out of the acini due to cardiogenic oscillations is a very small portion of the total gas eliminated during IPPV."
11/01/1998 - "The efficacy of nasal intermittent positive pressure ventilation (NIPPV) in treating apnea of prematurity was evaluated. "
11/01/1998 - "Efficacy of nasal intermittent positive pressure ventilation in treating apnea of prematurity."
10/01/2011 - "[Nasal synchronized intermittent positive pressure ventilation for the treatment of apnea in preterm infants]."
08/01/2010 - "The unique presenting symptom was apnea, which required respiratory support by nasal intermittent positive pressure ventilation. "